Full-Time

Associate Director AI Clinical Scientist

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$169.2k - $253k/yr

+ Incentive opportunity

Princeton, NJ, USA

In Person

Category
Biology & Biotech (1)
Required Skills
LLM
Data Science
TensorFlow
PyTorch
Machine Learning
Data Analysis

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • At least 5 years of experience in artificial intelligence and advanced data sciences within pharmaceutical or biotechnology research and development industries.
  • Expertise in scientific data analyses for drug development and real-world data assets, including exploration of biomarkers, endpoints, and scientific or value evidence.
  • Proficiency in artificial intelligence, generative artificial intelligence, and machine learning techniques and relevant tools such as PyTorch, TensorFlow, large language models, and related technologies for analyses and analytics.
  • Expertise in digital health technologies and their applications in pharmaceutical research.
  • Strong project management skills focused on delivering impactful initiatives.
Responsibilities
  • Implement Data Science and AI portfolio objectives and contribute to data and analysis strategies across all phases of drug development, from discovery and preclinical to clinical stages, while extensively leveraging artificial intelligence.
  • Identify and apply innovative analytical solutions, including novel artificial intelligence tools, methodologies, technologies, machine learning, tokenization, and digital health technologies.
  • Develop and apply advanced analyses for biological data, including digital and sensor data, metabolomics, proteomics, and genomics, to support new drug development and decision-making.
  • Investigate and conduct proof-of-concept initiatives and develop solutions for new artificial intelligence applications using large language models and generative artificial intelligence to enhance data analytics and accelerate candidates across drug development phases.
  • Assess the feasibility and potential impact of integrating generative artificial intelligence, large language models, and other small artificial intelligence models into existing workflows, and recommend adoption strategies based on proof-of-concept outcomes.
  • Work with cross-functional teams to support scientific data analyses and leverage artificial intelligence and generative artificial intelligence capabilities for the drug development portfolio and evidence-generation efforts throughout the drug lifecycle.
  • Leverage generative artificial intelligence and artificial intelligence/machine-learning applications across the organization and create awareness and integration of these technologies into research and development processes.
  • Develop processes to optimize data and analytics systems and their execution in alignment with technological advancements.
  • Guide the scientific and technical evaluation, selection, and planning of analyses for transitional and digital biomarkers and data generated in clinical trials.
  • Lead the planning, development, and implementation of data-science solutions that leverage novel artificial intelligence methodologies.
  • Guide team members on artificial intelligence and other methodologies and foster innovation and collaborative success.
  • Collaborate with internal and external stakeholders to identify opportunities for innovation and experimentation with emerging technologies in data science and analytics.
  • Serve as a subject-matter expert and ensure effective awareness, communication, and collaboration to achieve portfolio success.
  • Remain current with industry trends and advancements in artificial intelligence and machine learning and provide insights to influence the organization's technical roadmap and strategy.
  • Build an internal and external presence through publications in relevant conferences and journals.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.